Efficacy, Effectiveness and Real Life Goal Attainment of Statins in Managing Cardiovascular Risk

Overview

Journal Vasc Health Risk Manag

Publisher Dove Medical Press

Specialty Cardiology & Vascular Diseases

Date 2009 May 30

PMID 19475774

Citations 8

Authors

Naila Goldenberg

Charles Glueck

Affiliations

Soon will be listed here.

Abstract

Statins became available for the treatment of hypercholesterolemia in 1987. Multiple, well-designed, placebo-controlled, double-blind studies revealed that each 1% reduction in serum cholesterol level was associated with about 1% reduction in risk of cardiovascular events. Low-density lipoprotein (LDL) cholesterol reduction to less than 78 mg/dL may be associated with reduction of atheroma burden. Patients with high levels of high specificity C-reactive protein and having LDL cholesterol less than 3.4 mmol/L (130 mg/dL) in primary prevention settings benefited from aggressive LDL cholesterol reduction with rosuvastatin over a 2-year period. However, in real life practice, about half of patients who are prescribed statins discontinue the medication by the end of the year. Medication adherence is lower in younger patients, women, and absence of known coronary heart disease. Personal features of the prescribing physician and dispensing pharmacies also affect patients' compliance. More studies are needed to evaluate if "compliance packets" would benefit patients in a real life situation.

Citing Articles

Pharmacoepidemiology Research-Real-World Evidence for Decision Making.

Berard A Front Pharmacol. 2021; 12:723427.

PMID: 34557096 PMC: 8452957. DOI: 10.3389/fphar.2021.723427.

Discovery of a Lead Triphenylethanamine Cholesterol Ester Transfer Protein (CETP) Inhibitor.

Finlay H, Jiang J, Rampulla R, Salvati M, Qiao J, Wang T ACS Med Chem Lett. 2019; 10(6):911-916.

PMID: 31223447 PMC: 6580557. DOI: 10.1021/acsmedchemlett.9b00086.

Statin prescription strategies and atherogenic cholesterol goals attainment in Lebanese coronary artery disease patients.

Lama S, Souraya D, Youssef F Int J Clin Pharm. 2017; 39(4):919-926.

PMID: 28523462 DOI: 10.1007/s11096-017-0483-x.

Pharmacological primary and secondary cardiovascular prevention among diabetic patients in a multiethnic general practice population: still room for improvements.

Tran A, Straand J, Dalen I, Birkeland K, Claudi T, Cooper J BMC Health Serv Res. 2013; 13:182.

PMID: 23688317 PMC: 3664587. DOI: 10.1186/1472-6963-13-182.

A systematic review of economic evaluations of interventions to tackle cardiovascular disease in low- and middle-income countries.

Suhrcke M, Boluarte T, Niessen L BMC Public Health. 2012; 12:2.

PMID: 22214510 PMC: 3299641. DOI: 10.1186/1471-2458-12-2.

References

Pedan A, Varasteh L, Schneeweiss S . Analysis of factors associated with statin adherence in a hierarchical model considering physician, pharmacy, patient, and prescription characteristics. J Manag Care Pharm. 2007; 13(6):487-96. PMC: 10437851. DOI: 10.18553/jmcp.2007.13.6.487. View

Perreault S, Blais L, Lamarre D, Dragomir A, Berbiche D, Lalonde L . Persistence and determinants of statin therapy among middle-aged patients for primary and secondary prevention. Br J Clin Pharmacol. 2005; 59(5):564-73. PMC: 1884848. DOI: 10.1111/j.1365-2125.2005.02355.x. View

Nissen S, Tuzcu E, Schoenhagen P, Brown B, Ganz P, Vogel R . Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004; 291(9):1071-80. DOI: 10.1001/jama.291.9.1071. View

Sacks F, Pfeffer M, Moye L, Rouleau J, Rutherford J, Cole T . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996; 335(14):1001-9. DOI: 10.1056/NEJM199610033351401. View

Baigent C, Keech A, Kearney P, Blackwell L, Buck G, Pollicino C . Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366(9493):1267-78. DOI: 10.1016/S0140-6736(05)67394-1. View

Riccioni G, Bazzano L, Bucciarelli T, Mancini B, Di Ilio E, DOrazio N . Rosuvastatin reduces intima-media thickness in hypercholesterolemic subjects with asymptomatic carotid artery disease: the Asymptomatic Carotid Atherosclerotic Disease in Manfredonia (ACADIM) Study. Expert Opin Pharmacother. 2008; 9(14):2403-8. DOI: 10.1517/14656566.9.14.2403. View

. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344(8934):1383-9. View

Ridker P, Paynter N, Rifai N, Gaziano J, Cook N . C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008; 118(22):2243-51, 4p following 2251. PMC: 2752381. DOI: 10.1161/CIRCULATIONAHA.108.814251. View

Ridker P, Rifai N, Clearfield M, Downs J, Weis S, Miles J . Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med. 2001; 344(26):1959-65. DOI: 10.1056/NEJM200106283442601. View

10.

Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A . A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess. 2007; 11(14):1-160, iii-iv. DOI: 10.3310/hta11140. View

11.

Schmidt W, Spiel A, Jilma B, Wolzt M, Muller M . In-vivo effects of simvastatin and rosuvastatin on global gene expression in peripheral blood leucocytes in a human inflammation model. Pharmacogenet Genomics. 2008; 18(2):109-20. DOI: 10.1097/FPC.0b013e3282f44d81. View

12.

Kinlay S . Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol. 2007; 49(20):2003-9. DOI: 10.1016/j.jacc.2007.01.083. View

13.

Robinson J, Smith B, Maheshwari N, Schrott H . Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol. 2005; 46(10):1855-62. DOI: 10.1016/j.jacc.2005.05.085. View

14.

Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R . European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Atherosclerosis. 2007; 194(1):1-45. DOI: 10.1016/j.atherosclerosis.2007.08.024. View

15.

Cannon C, Braunwald E, McCabe C, Rader D, Rouleau J, Belder R . Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004; 350(15):1495-504. DOI: 10.1056/NEJMoa040583. View

16.

Riesen W, Noll G, Dariolo R . Impact of enhanced compliance initiatives on the efficacy of rosuvastatin in reducing low density lipoprotein cholesterol levels in patients with primary hypercholesterolaemia. Swiss Med Wkly. 2008; 138(29-30):420-6. DOI: 10.4414/smw.2008.12120. View

17.

Mayer C, Gruber H, Landl E, Pailer S, Scharnagl H, Truschnig-Wilders M . Rosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3- and C/EBP-dependent fashion. Int J Clin Pharmacol Ther. 2007; 45(6):319-27. DOI: 10.5414/cpp45319. View

18.

Kotseva K, Stagmo M, De Bacquer D, De Backer G, Wood D . Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II survey. Atherosclerosis. 2007; 197(2):710-7. DOI: 10.1016/j.atherosclerosis.2007.07.004. View

19.

Jones P, Davidson M, Stein E, Bays H, McKenney J, Miller E . Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003; 92(2):152-60. DOI: 10.1016/s0002-9149(03)00530-7. View

20.

Grundy S, Cleeman J, Merz C, Brewer Jr H, Clark L, Hunninghake D . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol. 2004; 44(3):720-32. DOI: 10.1016/j.jacc.2004.07.001. View